anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study was a prospective, nonrandomized pilot study conducted among adults with uncontrolled diabetes admitted to the Medicine Service of an urban tertiary teaching hospital were consented to participate in a pilot study which provided diabetes survival skills education. Based on knowledge deficits identified on a diabetes knowledge pre-test the patient was directed to view video content corresponding to those deficiencies and content on sick days and diabetes complications. Evaluation measures were diabetes knowledge, medication adherence, and hospital admissions plus emergency department visits at and/or 3months before baseline and at 2 weeks and 3 months post-discharge. There was improvement in diabetes knowledge and medication adherence, which was sustained to 3 months. A trend was observed toward reduction in emergency department and/or hospital admissions from 3 months pre-intervention to 3 months post-discharge for uncontrolled diabetes. This knowledge-based program successfully provided survival skills education to hospital patients with uncontrolled diabetes and demonstrated preliminary evidence of a positive impact on medication adherence and a trend toward reduction in hospital and emergency department admissions.
During baseline-controlled clinical trials, in patients receiving digitalis and diuretics, single doses of lisinopril resulted in decreases in pulmonary capillary wedge pressure, systemic vascular resistance and blood pressure accompanied by an increase in cardiac output and no change in heart rate.

In two placebo controlled, 12 week clinical studies using doses of lisinopril up to 20 mg, lisinopril as adjunctive therapy to digitalis and diuretics improved the following signs and symptoms due to congestive heart failure: edema, rales, paroxysmal nocturnal dyspnea and jugular venous distention. In one of the studies, beneficial response was also noted for: orthopnea, presence of third heart sound and the number of patients classified as NYHA Class III and IV. Exercise tolerance was also improved in this study. The once-daily dosing for the treatment of congestive heart failure was the only dosage regimen used during clinical trial development and was determined by the measurement of hemodynamic response. A large (over 3000 patients) survival study, the ATLAS Trial, comparing 2.5 and 35 mg of lisinopril in patients with heart failure, showed that the higher dose of lisinopril had outcomes at least as favorable as the lower dose.
PURPOSE:To carry out bonding of a resin to dentine, by treating the surface of dentine with a treating liquid produced by adding glutaraldehyde and FeCl3 to an aqueous solution of EDTA adjusted to a specific pH, washing the surface- treated dentine with water, drying the surface, applying a primer added with tri-n-butylborane to the dentine and bonding with a resin. CONSTITUTION:(A) An aqueous solution of EDTA adjusted to pH7.4 is added with (B) glutaraldehyde and (C) FeCl3 to obtain a dentine-treating liquid (the concentrations of the compounds A, B and C are 0.1-1.0mol./l, 0.01-20pts.wt. and 0.01-5.00pts.wt. per 100pts.wt. of water, respectively). The surface of dentine is treated with the obtained dentine-treating liquid, washed with water, dried and coated with a primer composed of an ethylenic unsaturated monomer [e.g. (meth)acrylate monomer], a (meth)acrylate polymer and tri-n-butylborane. A restoration composite resin is filled in a cavity of the treated dentine. The above treating liquid has high safety, is effective in simplifying the process and provides good bonded state.
Cirrhosis is a liver disease that leads to increased intrahepatic resistance, portal hypertension (PH), and splanchnic hyperemia resulting in ascites, variceal bleeding, and hepatorenal syndrome. Terlipressin, a prodrug that converts to a short half-life vasopressin receptor 1 A (V1a) full agonist [8-Lys]-Vasopressin (LVP), is an intravenous treatment for PH complications, but hyponatremia and ischemic side effects require close monitoring. We developed PHIN-214 which converts into PHIN-156, a more biologically stable V1a partial agonist. PHIN-214 enables once-daily subcutaneous administration without causing ischemia or tissue necrosis and has a 10-fold higher therapeutic index than terlipressin in healthy rats. As V1a partial agonists, PHIN-214 and PHIN-156 exhibited maximum activities of 28 % and 42 % of Arginine vasopressin (AVP), respectively. The potency of PHIN-156 and LVP relative to AVP is comparable for V1a (5.20 and 1.65 nM, respectively) and V1b (102 and 115 nM, respectively) receptors. However, the EC50 of PHIN-156 to the V2 receptor was 26-fold higher than that of LVP, indicating reduced potential for dilutional hyponatremia via V2 agonism compared to terlipressin/LVP. No significant off-target binding to 87 toxicologically relevant receptors were observed when evaluated in vitro at 10 µM concentration. In bile duct ligated rats with PH, subcutaneous PHIN-214 reduced portal pressure by 13.4 % ± 3.4 in 4 h. These collective findings suggest that PHIN-214 could be a novel pharmacological treatment for patients with PH, potentially administered outside of hospital settings, providing a safe and convenient alternative for managing PH and its complications.
1519149 Device for percutaneous administration of medicaments FISONS Ltd 17 Nov 1975 [30 Nov 1974] 51941/74 Headings A5B and A5R A means for the extended systemic administration of a medicament through the skin of an animal comprises a device having a basal surface area adapted to contact the skin of the animal and having one or more depressions in said area which contain a non- mobile systemic medicament composition containing a carrier capable of transmitting the medicament through the skin, said device having non-adhesive means for its attachment to the animal so that the basal surface area and the medicament composition are in contact with the skin of the animal. The device or its base may be made of flexible resilient material and it may be attached by straps, pins, clips or staples to e.g. the ear or tail of the animal. The medicament may be a travel-sickness mitigator, an anti-migraine compound, an analgesic or a parasiticide, in solution in the carrier which may be e.g. a ketone, an alcohol or a hydrocarbon and dimethylsulphoxide. The solution is rendered non-mobile by absorption on a porous support material such as clay, rigid foam or cotton wool or by being in the form of a cream, paste or gel.
[GB1519149A]
PURPOSE: A pharmaceutical composition containing phenyl butyric acid is provided to reduce inflammatory cell and cytokine expression, airway inflammation, and airway hyperresponsiveness. CONSTITUTION: A pharmaceutical composition for preventing or treating bronchial inflammation and asthma contains 4-phenylbutyric acid of chemical formula 1 or pharmaceutically acceptable salt thereof as an active ingredient. The asthma is acute asthma caused by bacterial infection. The pharmaceutical composition additionally contains pharmaceutically acceptable carrier, excipient, or diluents. A health functional food contains the compound of chemical formula 1 as an active ingredient. The health functional food is manufactured in the form of a tablet, capsule, pill, or liquid.
ARDS patients with circulatory or organ hypoperfusion problems should use as little fluid as possible to maintain treatment and circulation; other ARDS patients should focus on stabilizing circulation during the resuscitation phase, with controlled fluid replacement combined with early vasoactive drugs; ultrasound, Central venous pressure measurement, mixed central venous oxygen saturation, alveolar-arterial oxygen difference, blood lactate, etc. guide fluid resuscitation therapy; stop using vasoactive drugs for more than 12 hours, and use diuretics or diuretics combined with albumin to achieve fluid balance.
Provided is a drug for preventing, alleviating or treating adhesion and a use thereof. A fibroblast which has been subjected to external stimulation in a body cavity contains an activated negative regulatory receptor PEAR1. The deletion of the fibroblast PEAR1 can significantly promote in vivo mucosal adhesion formation. A PEARI agonist can specifically inhibit fibroblast activation, synthesize an extracellular matrix, and ameliorate the adhesion lesion. By administering the PEARI agonist, the formation of adhesion can be effectively prevented. Also provided is a PEARI agonistic antibody that does not affect the repair and healing of normal tissue and does not cause the tissue to be in an anoxic state. Moreover, the antibody drug has a long half-life, is easily diffused, has few side effects, and has a convenient route of administration.
Healthy male or female subjects aged 60 years or older, who received 2 doses of herpes zoster subunit vaccine (GSK1437173A) high dose (HD) formulation, according to a 0, 2-month schedule. The vaccine was administrated by (IM) in the upper deltoid site of the left arm.
Background and Objectives: Muscle atrophy caused by chronic ankle instability (CAI) can incur muscle weakness, altered movement patterns, and increased risk of injury. Previous studies have investigated the effects of rehabilitative exercises and neuromuscular electrical stimulation (NMES) on characteristics in CAI individuals, but few studies have examined their effects on foot and ankle muscle morphology. This study aimed to determine the effects of rehabilitative exercises and NMES on muscle morphology and dynamic balance in individuals with CAI. Materials and Methods: Participants with CAI (n = 47) were randomly divided into control (CG), rehabilitative exercise (REG), NMES (NG), and rehabilitative exercise and NMES combined (RNG) groups. The six-week intervention program consisting of rehabilitative exercises and NMES was applied to groups excluding CG. Muscle morphology and dynamic balance were evaluated using a portable wireless diagnostic ultrasound device and dynamic balance tests. For statistical analysis, an effect size with 95% confidence interval was calculated to assess mean differences according to intervention. Results: After six weeks, significant increases in morphology and dynamic balance were observed for all muscles except flexor hallucis longus (p > 0.05) in the intervention groups except for CG. However, no significant changes were observed in the CG (p > 0.05). Conclusions: These findings suggest that intervention programs may help prevent muscle atrophy and improve balance in CAI individuals.
A substantially anhydrous cosmetic composition having a lamellar network including: (a) about 20 to about 84.5 wt. % of one or more glycols chosen from ethylene glycol, propylene glycol, butylene glycol, hexylene glycol, pentylene glycol, diethylene glycol, dipropylene glycol, 1,3 propanediol, polyethylene glycols, and a mixture thereof; (b) about 15 wt. % to about 50 wt. % of one or more trihydric alcohols having from 3 to 5 carbon atoms; wherein the total amount of the one or more glycols of (a) is greater than the total amount of the one or more trihydric alcohols of (b); (c) about 0.1 to about 5 wt. % of one or more cationic surfactants; (d) about 0.1 to about 5 wt. % one or more alkoxylated fatty alcohols; and (e) about 0.1 to about 10 wt. % of one or more fatty alcohols, wherein all percentages by weight are based on the total weight of the cosmetic composition.
PROBLEM TO BE SOLVED: To produce the subject troche staying for a long time, having a good feeling in being applied, having a long time durability, causing no dental caries when staying for a long time and excellent in safety by including xylitol and/or erythritol in a controlled release tablet having an adhesive layer and a non- adhesive one respectively to oral mucosa. SOLUTION: This troche is produced by including (B) xylitol and/or erythritol in (A) a controlled release tablet having an adhesive layer and a non-adhesive one respectively to oral mucosa. An adhesive component polymer of the adhesive layer is pref. sodium polyacrylate included in a quantity of 5-100% based on the adhesive layer. The troche as therapeutic agent against periodontal disease pref. includes 10-60% component B in the adhesive component polymer and pref. include 30-90% component B in the non-adhesive layer. The weight of one of the tablets is pref. 0.1-0.7 g. The weight ratio of (adhesive layer/non- adhesive layer) is pref. (2/98)-(80/20).
Substance use disorders are among the most important problems of our time. It has become a public health problem which is very common in developed and developing countries and affects the individual and the family as well as the society. Treatment of this problem, which leads to important disorders in many parts of individuals' lives, is quite difficult. Primary treatment is carried out by pharmacological methods. In cases where pharmacological methods are not sufficient, treatment is supported with psycho-social methods.

The aim is to identify the effect of mindfulness-based education, which is in accordance with self-efficacy theory, given to individuals who have substance abuse disorders.

The research was planned as a test model with pretest-posttest control groups. Individuals who have been diagnosed with substance abuse in the substance abuse clinic of Turgut Özal Medical Center, and at the Substance Abuse Treatment and Education Centre of Gaziantep 25 Aralık State Hospital formed the core of this study. The research was conducted between January 2018-May 2019. 112 patients, 56 in the treatment and 56 in the control group, participated in the study. Scientific research started after ethical approval. Mindfulness therapy was applied to experimental group patients. For the data collection, the Socio-Demographic Characteristics Questionnaire and Self-Efficacy scale were used. Kolmogorov-smirnov distribution test was used for normal distribution and Cronbach's alpha was used for internal consistency. Percentage, mean and standard deviation in evaluation of patients' demographic data, chi-square test in parametric cases in comparison of control variables of experimental and control groups, Fisher's exact test in non-parametric cases, t-test in dependent groups in comparison of mean scores of experimental and control groups, score in test and control groups in itself. t test was used in independent groups.
Collegiate athletes must satisfy the academic obligations common to all undergraduates, but they have the additional structural and social stressors of extensive practice time, competition schedules, and frequent travel away from their home campus. Clearly such stressors can have negative impacts on both their academic and athletic performances as well as on their health. These concerns are made more acute by recent proposals and decisions to reorganize major collegiate athletic conferences. These rearrangements will require more multi-day travel that interferes with the academic work and personal schedules of athletes. Of particular concern is additional east-west travel that results in circadian rhythm disruptions commonly called jet lag that contribute to the loss of amount as well as quality of sleep. Circadian misalignment and sleep deprivation and/or sleep disturbances have profound effects on physical and mental health and performance. We, as concerned scientists and physicians with relevant expertise, developed this white paper to raise awareness of these challenges to the wellbeing of our student-athletes and their co-travelers. We also offer practical steps to mitigate the negative consequences of collegiate travel schedules. We discuss the importance of bedtime protocols, the availability of early afternoon naps, and adherence to scheduled lighting exposure protocols before, during, and after travel, with support from wearables and apps. We call upon departments of athletics to engage with sleep and circadian experts to advise and help design tailored implementation of these mitigating practices that could contribute to the current and long-term health and wellbeing of their students and their staff members.
PURPOSE:To obtain a cosmetic having excellent slipperiness and adhesive feeling to the skin, etc., by charging a powdery cosmetic raw material into a prescribed container, dispersing the raw material with ultrasonic waves, previously compression forming the dispersion, compressing and then molding the resultant previously formed compact with a pressing unit. CONSTITUTION:A powdery cosmetic raw material 6 is placed in a container 1 and ultrasonic waves are oscillated from a compressing rod 4 on the upper side thereon to disperse and previously compression form the raw material 6. The previously formed raw material is then compressed and formed with a pressing unit consisting of the upper and lower compressing rods 4 and 5 to afford a compression formed product (such as rouge, eye shadow, compact, powders or kneaded foundation) which is a powdery cosmetic. The raw material is converted into a homogeneous dispersed state by previous compression forming with the ultrasonic waves. Since almost an uniform particle diameter is attained, the aimed cosmetic having excellent slipperiness and adhesive feeling to the skin is obtained. Since the previous compression is carried out, small pressurizing force with the pressing unit is sufficient and forming can be readily performed by using even a container of a special shape.
The invention belongs to the field of biomedicine, and relates to a preparation method and application of a Kabuki syndrome brain-like organ model. The invention provides application of a GSK-3 inhibitor in preparation of a medicine for treating Kabuki syndrome. The currently available Kabuki models include heterozygous mouse, zebrafish, and 2D human cell models. However, the complexity of human brain development in non-animal models is comparable to that of a single 2D cell model. In the invention, the KMT2D is knocked out by using CRISPR-CAS9 gene editing technology, and a Kabuki syndrome brain-like organ model is established by using brain-like organ technology. Research shows that the Kabuki syndrome brain-like organ has excessive GABAergic neuron differentiation in advance compared with the wild type. By testing the addition dosage and time window of the small molecule chir99021, the small molecule can restore the abnormal neuron differentiation phenotype in the brain-like organ of the Kabuki syndrome. This finding will provide a new concept for the treatment of Kabuki syndrome.
The control group will be given min. 5 slices of bread baked with yeast per day.
The invention relates to a preparation method of biodegradable interpenetrating network polymer microspheres. Firstly a low molecular weight sodium alginate aqueous solution is prepared. The sodium alginate aqueous solution is partially oxidized into an aldehyde function group (oxidisability controlled within 10-40%). Further a carboxymethyl chitosan aqueous solution is prepared. Both solutions are mixed uniformly according to different ratios, and are suspended in paraffin oil and stirred at high speed to form an emulsion. The emulsion is heated and dehydrated through vacuum pressure reduction. The microspheres are filtered out and dried, and small balls with the diameter between 310-550microns are prepared. In the microspheres, the sodium alginate and the carboxymethyl chitosan form a special interpenetrating network structure. Two polymers also form crosslinking points through electrostatic adsorption and chemical reaction of amino and aldehyde groups except that chain segments are interlaced together. The microspheres have regular structure, stable performance, high load rate for doxorubicin, and are degraded within several months in a simulation body fluid, thereby possessing application prospect of biomedical materials.
PURPOSE:To increase the quantity of information for medical diagnosis and to secure more highly accurate diagnosis by writing the individual identification data and the test data to a memory card at a hospital and also writing other data to the card at a patient private house. CONSTITUTION:The individual identification data are written to a memory card 15 at a hospital by a computer 10 and at the same time the test data on a biochemical test and other tests are also written successively to the card 15. While a paitient receives the card 15 written at the hospital side and performs periodically an everyday test at his/her own home to write these everyday test data including the blood pressure, etc., onto the card 15. Such a card 15 is read by the computer 10 at the hospital and the card contents are displayed on a CRT 12. As a result, a doctor can also know the transition of the blood pressure, etc., checked at the patient own home is addition to various check data obtained at the hospital. Thus the medical diagnosis is secured with higher accuracy.
Scalp-targeted rTMS will be delivered using standard BEAM F3 targeting methodology to target the dlPFC. rTMS will last approximately 30 minutes (3000 pulses total) and will be delivered at 120% of the participant's motor threshold. Participants will be monitored during the rTMS session for adverse events and/or side effects.
The present invention relates to a formula of a capsule prepared from pumpkin as a main raw material for treating constipation and a preparation method of the capsule. The ubiquitous problems of traditionally cathartic products are mainly solved that drastic purgative components as main bodies can cause stomachache, diarrhea, humoral imbalance, enteric plexus nerve damage, etc. after taken, and dependence phenomena can occur easily; in addition, materials processed by a traditional technology have the disadvantages of insufficient grain fineness, low biological availability and unfavorable clinic effect. The present invention has the technical scheme that the capsule is made from 7 raw materials of pumpkin peel, pumpkin stalk, pumpkin collateral, Poria, tremella, xylo oligosaccharide and aloe. The preparation method comprises the following steps: impurity removing, extracting, decocting, low temperature drying and superfine grinding processing. The capsule of the present invention is suitable for treating intractable constipation caused by various reasons for old and frail persons, puerpera, children, postoperative patients, etc., and has the advantages of low dosage, rapid effect taking, comfortable defecation and no stomachache and diarrhea. The normally physiological defecation of most patients with intractable constipation can be realized after the capsule is consecutively taken for nearly 1 month.
During major urological surgery (i.e. cistectomy) investigators will use a minimally invasive hemodynamic monitoring system (Flotrac - Vigileo, Edwards ) to guide fluid therapy and vasopressors administration. More specifically stroke volume target will be defined as the maximum SV after a series of fluid boluses, with a 10% tolerance. MAP was considered adequate if above 65 mmHg. After the induction of anesthesia, then each hour during surgery until the end of surgical procedure investigators will assess the time of adherence to the hemodynamic protocol (in terms of both SV and MAP) and the correspondent pCO2 gap. Investigators expect to find an inverse proportionality between the two parameters explored.
PURPOSE:An external agent for the skin, containing pantetheine-S-sulfonic acid and/or a salt thereof, and capable of inhibiting then irritation of a base and an drug active constituent without affecting the pharmaceutical stability. CONSTITUTION:An external agent for the skin obtained by dissolving, dispersing or mixing a drug active constituent in a base, e.g. vaseline, liquid paraffin or fat, and incorporting pantetheine-S-sulfonic acid or a salt thereof in an amount of 0.5% or more, preferably 1-20%, and if necessary adding a penetrant or kerationous softening agent thereto. The dosage form thereof is a solution, ointment or powder. The pantetheine-S-sulfonate which is an active constituent is an easily handleable powder having a high solubility in water at a low cost. The compound is useful as a precursor for coenzyme A playing an important role in the energy metabolism in the living body.